Hengrui Medicine And Hansoh Pharmaceutical To Set Up Pharmaceutical R&D Base
This article was originally published in PharmAsia News
Jiangsu Hengrui Medicine and Jiangsu Hansoh Pharmaceutical recently began construction of their co-funded pharmaceutical industry park in Lianyungang Economic and Technological Development Zone. The two Jiangsu companies will jointly invest RMB 3 billion ($439 million) to build a U.S. and EU standards-compliant pharmaceutical formulation plant, office building, R&D center and auxiliary facilities. Covering an area of 40 hectares, the base will build workshops for formulations of solid, freeze-dried powder and injections, transfusion fluids, contrast agents and bioproducts. The RMB 1.2 billion ($175 million) phase I project is targeted to finish by 2011, while the entire project will be completed within five years. The two companies plan to launch five to six Class I new drugs of original IP rights in the next five years. (Click here for more - Chinese Language)
You may also be interested in...
Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.